The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2019
Filed:
Aug. 23, 2018
Applicant:
Pathologica Llc, San Francisco, CA (US);
Inventors:
Jeremy Blitzer, San Francisco, CA (US);
John McKearn, St. Louis, MO (US);
Assignee:
Pathologica LLC, San Francisco, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/15 (2006.01); A61K 31/137 (2006.01); A61K 38/03 (2006.01); A61K 38/21 (2006.01); A61K 31/136 (2006.01); A61K 31/155 (2006.01); A61K 31/225 (2006.01); A61K 31/277 (2006.01); A61K 31/4704 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/15 (2013.01); A61K 9/0053 (2013.01); A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/225 (2013.01); A61K 31/277 (2013.01); A61K 31/4704 (2013.01); A61K 38/03 (2013.01); A61K 38/21 (2013.01);
Abstract
Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.